Thirona, a leader in AI-driven lung analysis, has received FDA 510(k) clearance for the latest update, LungQ v3.0.0. This milestone enables U.S. hospitals to utilise the advanced capabilities of LungQ, a cutting-edge technology in lung disease diagnosis and treatment. The software automatically segments and analyses intricate lung anatomy, identifying key structures like lobes, segments, airways, and fissures.
LungQ facilitates detailed tissue analysis, supporting accurate diagnoses based on individual CT scans, and guides bronchoscopic navigation with precision for minimally invasive interventions such as lung cancer biopsies and volume reduction therapies. Thirona's CEO, Eva van Rikxoort, emphasises the transformative impact of this technology, opening doors to personalised, minimally invasive lung care and paving the way for a new era in healthcare.
With over 600 hospitals and 200 publications already leveraging LungQ's capabilities, the FDA clearance represents a significant step in expanding its global reach. Hospitals in the United States can now benefit from this innovative AI technology, contributing to improved outcomes for lung patients worldwide.
Thirona's LungQ 3.0.0 highlights the transformative potential of AI in healthcare, offering a deep dive into the hidden landscapes of the lungs and shaping a future where personalised, minimally invasive lung care becomes the standard, providing hope and better health for millions.
Click here to read the original news story.